|
|
|
| Evaluation of the Effect of Ziprasidone in the Treatment of Patients with Refractory Schizophrenia Based on PANSS Score and Serum Cytokine Levels |
| HU Wenfang, LAN Bin, HUANG Li |
| First-author's address: Third People's Hospital of Ganzhou, Jiangxi Province, Ganzhou 341000, China |
|
|
|
|
Abstract Objective: To investigate the effect of Ziprasidone in the treatment of patients with refractory schizophrenia and its effect on the scores of the positive and negative syndrome scale (PANSS) and serum cytokine levels in patients with schizophrenia. Method: A total of 82 patients with refractory schizophrenia admitted to Third People's Hospital of Ganzhou from January 2019 to January 2022 were selected as the research objects and divided into the observation group (n=41) and the control group (n=41) by random number table method. The control group was treated with Olanzapine, and the observation group was treated with Ziprasidone based on the control group. Both groups were treated for 6 weeks. The clinical efficacy after treatment was compared between the two groups. PANSS score, serum levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), 5-hydroxytryptamine (5-HT), glial fibrillary acidic protein (GFAP), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α) before and after treatment and the occurrence of adverse reactions during treatment were compared. Result: After treatment, the total clinical effective rate of patients in the observation group was higher than that in the control group (P<0.05); positive symptoms, negative symptoms, general psychopathological symptoms and total score, the levels of serum GFAP, IL-2, IL-6, TNF-α, IL-17 in the observation group were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05); the levels of serum BDNF, NGF and 5-HT in the two groups after treatment were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). During the treatment, the total incidence of adverse reactions in the observation group was lower than that in the control group, with a statistically significant difference (P<0.05). Conclusion: The application of Ziprasidone in the treatment of refractory schizophrenia can effectively improve the psychiatric symptoms, relieve neuronal stress response, reduce neuronal damage, reduce inflammation, with significant efficacy and high safety.
|
|
Received: 24 October 2022
|
|
|
|
|
|
|
